Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination.

Lansky, Alexandra; Shah, Tayyab; Wijns, William; Stefanini, Giulio G; Farb, Andrew; Kaplan, Aaron; Xu, Bo; Pietras, Cody; Velazquez, Eric; Serruys, Patrick W; Mahfoud, Felix; Baumbach, Andreas

Lansky, Alexandra; Shah, Tayyab; Wijns, William; Stefanini, Giulio G; Farb, Andrew; Kaplan, Aaron; Xu, Bo; Pietras, Cody; Velazquez, Eric; Serruys, Patrick W; Mahfoud, Felix; Baumbach, Andreas.

Lansky A; Yale University School of Medicine, New Haven, CT, USA.

EuroIntervention ; 16(10): 787-793, 2020 Nov 20.

Article in English | MEDLINE | ID: covidwho-937605

Subject(s)

COVID-19; Cardiovascular Diseases; Endpoint Determination; Cardiovascular Diseases/therapy; Clinical Trials as Topic; Humans; Pandemics; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Endpoint Determination / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: EuroIntervention Journal subject: Vascular Diseases / Cardiology / Therapeutics Year: 2020 Document Type: Article Affiliation country: EIJV16I10A147

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google